Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

al clinical development for Shire Pharmaceuticals. Prior to joining Shire, Ms. Keller was head of development operations and clinical trial recruitment services for Pfizer Global Research and Development.

An integral part of the company's launch plans for all its diagnostic products is ensuring ongoing dialogue with managed care providers. Joseph Zimmerman recently joined SEQUENOM to oversee this function as vice president of managed care. Previously, Mr. Zimmerman held a number of positions at AmeriPath, most recently as vice president of managed care. Prior to joining AmeriPath, Mr. Zimmerman served as director of managed care, Midwest Division, LabCorp.

2009 Guidance

SEQUENOM is updating its 2009 financial guidance as follows:

Genetic Analysis:

  • Revenues to range between $32 million and $35 million.
  • Gross margin of approximately 57% in 2009.
  • Net loss of approximately $11 million.
  • Cash burn of breakeven to $2 million.

Molecular Diagnostics

  • Revenue guidance is not being provided.
  • Net loss of approximately $54 million.
  • Cash burn of approximately $52 million to $55 million.

Consolidated

  • Net loss of approximately $65 million, which includes approximately $12 million in non-cash FAS 123R expenses.
  • Cash burn of approximately $52 to $57 million. The increase in burn rate is due to increased legal expenses, and increased expenses associated with the ramp up of the company's diagnostics efforts.

About SEQUENOM

SEQUENOM is a life sciences company committed to providing the best genetic analysis products that translate the results of genomic science into solutions for molecular dia
'/>"/>

SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... BRM) ("Biorem" or "the Company") today announced its results for the three ... financial statements and MD&A have been filed on SEDAR ( www.sedar.com ). ... 2014 , 2013 Revenue 3,968 , 5,121 ... 1,703 , 2,231 , 5,866 Operating  expenses ... , 4,562 Ebitda* 92 , 418 , ...
(Date:4/29/2015)... 29, 2015 Cambrex Corporation (NYSE: CBM ) ... on Friday, May 1, 2015 before the market opens. ... will host a conference call to discuss the financial results. ... , Friday, May 1, 2015 at 8:30 a.m. ... for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem ... cell therapy has processed more than 11,000 samples. ... successful treatment for horses with potentially fatal injuries to ... worldwide exclusive license for adipose-derived (fat derived) stem cell ... treated in January 2004. Shortly after, the first dogs ...
(Date:4/29/2015)... 2015 /CNW/ - Northern Biologics Inc., a privately held ... an exclusive, strategic collaboration with Celgene Corporation.  As ... US$30 million upfront cash payment. It will use ... antibodies, and will have the right to receive ... its portfolio. Under the agreement, ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Nektar Therapeutics,(Nasdaq: NKTR ) announced today that ... NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals,have also ... additional,trials: a randomized Phase 2 study to evaluate NKTR-102 ... gene mutation, and a,Phase 2 study in metastatic breast ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been granted its 31st U.S. Patent, # ... The patent includes claims to pharmaceutical compositions containing ... our proprietary position for REOLYSIN(R)," said Mary Ann ...
... Support Development of Micromet,s EpCAM-specific Antibody Therapeutics BETHESDA, ... (Nasdaq: MITI ), a biopharmaceutical company ... cancer, inflammation and autoimmune diseases today announced the ... Nature Cell Biology (1) revealing a novel ...
Cached Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... at high latitudes grow better than their counterparts closer ... The study, published in the February issue of The ... Bergmann,s Rule, the observation that animals tend to be ... Bergmann made his observation about latitude and size in ...
... Centers for Disease Control and Prevention, the U.S. Food and ... and Inspection Service are investigating a multistate outbreak of Salmonella ... University of Iowa confirmed on Monday, Jan. 25, that this ... sickened 187 people in 39 states (one case in Iowa) ...
... Professor of Philosophy at Stevens Institute of Technology, was recently ... 2009 in History of Science by the History of Science ... Letters at Stevens, was co-author of the paper, "After the ... wrote the paper with Angela N. H. Creager, a Professor ...
Cached Biology News:Better food makes high-latitude animals bigger 2Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak 2
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Biology Products: